UI/UX、ロゴ、スライド、画像生成（7,292 件）
Architectures and techniques for neural operators on discontinuous PDE solutions (shocks, contact discontinuities, steep gradients). Covers local-global spectral design (ShockFNO), reflection padding for non-periodic BCs, resolution scaling for shock width, and frequency-band error diagnostics. Use for low-viscosity Burgers, compressible Euler, Riemann problems, or any PDE where standard FNO produces Gibbs oscillations.
日本語の概要は準備中です。原文の説明を表示しています。
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
Estimates the minimum biological replicates (or cells/events) for a target power at a target FDR in genomics experiments using ssizeRNA, PROPER, powsimR for scRNA-seq, and pilot-data dispersion estimation from DESeq2/edgeR. Covers the biological-versus-technical replication distinction (technical replicates do not add degrees of freedom for biological inference), replicate-number-versus-sequencing-depth budgeting, scRNA-seq sample-versus-cell allocation under a pseudobulk model, and the critique that "n=3" is a publication convention rather than a power calculation. Use when budgeting a sequencing experiment, writing the sample-size justification in a grant, estimating replicates from pilot data, allocating a fixed budget between samples and depth, or planning scRNA-seq cohort size. For clinical-trial sample size see clinical-biostatistics/power-and-sample-size; for the power-given-n direction see experimental-design/power-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Compound-target-disease network construction and analysis for drug repurposing, polypharmacology discovery, and multi-target drug design. Uses STRING, BioGRID, ChEMBL, DGIdb, OMIM, OpenTargets. Use for off-target effect prediction, network-based drug repurposing, and identifying molecules with desired multi-target profile.
日本語の概要は準備中です。原文の説明を表示しています。
De novo molecule generation for drug discovery. Scaffold-based analog enumeration, fragment growing/linking, structure-based design, multi-objective optimization, and drug-likeness filtering.
日本語の概要は準備中です。原文の説明を表示しています。
Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.
日本語の概要は準備中です。原文の説明を表示しています。
Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
日本語の概要は準備中です。原文の説明を表示しています。
Designs PROTACs, molecular glues, and bivalent degraders with explicit handling of E3 ligase choice (VHL, CRBN, IAP, MDM2, KEAP1), linker design (length, composition, rigidity), ternary complex prediction (PRosettaC, DeepTernary, AlphaFold3 with constraints), cooperativity (alpha), DC50 / Dmax characterization, hook effect, and prediction-experiment reconciliation. Use when designing targeted protein degraders, planning linker SAR, predicting ternary complex stability, or building generative degrader workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Performs retrosynthetic planning using AiZynthFinder (MCTS, template-based), Chemformer (template-free transformer), ASKCOS, and emerging RetroSynFormer with explicit handling of route scoring, building-block availability (eMolecules, Enamine, Mcule), forward prediction validation (Molecular Transformer), and disconnection-aware multi-objective search (MO-MCTS). Use when assessing synthetic feasibility of generated or selected molecules, planning multi-step syntheses, building synthesis-aware design pipelines, or screening libraries for retro-route feasibility.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes stable-isotope-resolved metabolomics (SIRM / isotope tracing / fluxomics) experiments that measure metabolic ACTIVITY via 13C/15N/2H tracers, distinct from steady-state pool profiling. Covers tracer choice, isotopologue vs isotopomer, mass-isotopomer distributions (MID), fractional enrichment, the mandatory natural-abundance + tracer-purity correction (IsoCor, AccuCor), and the metabolic/isotopic steady-state vs non-stationary (INST-MFA) distinction. Use when feeding a labeled tracer and interpreting labeling patterns, correcting raw isotopologue intensities, computing or plotting an MID, or deciding tracing vs abundance profiling. For absolute pool concentration and MRM mechanics see metabolomics/targeted-analysis; for constraint-based genome-scale flux (FBA, not empirical tracing) see systems-biology/flux-balance-analysis; for feature detection see metabolomics/xcms-preprocessing; for pathway enrichment that ignores the pool-vs-flux caveat see metabolomics/pathway-mapping.
日本語の概要は準備中です。原文の説明を表示しています。
AdwHeaderBar layout rules: button placement, flat/icon-only buttons, tooltips, title widgets, split buttons. Use when designing or fixing a GNOME app's header bar.
日本語の概要は準備中です。原文の説明を表示しています。
Add a standard GNOME preferences dialog (AdwPreferencesDialog) with Ctrl+comma shortcut, PreferencesPage/Group rows, and GSettings bindings. Use when adding settings or preferences UI to a GNOME app.
日本語の概要は準備中です。原文の説明を表示しています。
Exclusive-choice UI: CheckButton radio groups in list rows, when to use them vs ComboRow vs ToggleGroup. Use when presenting mutually exclusive options in GNOME preferences or dialogs.
日本語の概要は準備中です。原文の説明を表示しています。
UX designer and UI specialist. Use when the user asks to talk to Kaan or requests the UX designer.
日本語の概要は準備中です。原文の説明を表示しています。
System architect and technical design leader. Use when the user asks to talk to Tyler or requests the architect.
日本語の概要は準備中です。原文の説明を表示しています。
Plan UX patterns and design specifications. Use when the user says "lets create UX design" or "create UX specifications" or "help me plan the UX"
日本語の概要は準備中です。原文の説明を表示しています。
Create architecture solution design decisions for AI agent consistency. Use when the user says "lets create architecture" or "create technical architecture" or "create a solution design"
日本語の概要は準備中です。原文の説明を表示しています。
Agentic and machine-to-machine payments on Stellar. Covers x402 (HTTP 402 paid APIs via OZ Channels facilitator, fee-sponsored clients) and MPP (Machine Payments Protocol) in both Charge mode (per-request SAC) and Channel mode (off-chain commits, high-frequency). Defaults to USDC (SEP-41 SAC) on `stellar:testnet`/`stellar:pubnet` (CAIP-2). Use when selling a paid API to AI agents, building an x402 client, or designing a payment-channel architecture for high-frequency agent traffic.
日本語の概要は準備中です。原文の説明を表示しています。
React composition patterns that scale. Use when refactoring components with boolean prop proliferation, building flexible component libraries, or designing reusable APIs. Triggers on tasks involving compound components, render props, context providers, or component architecture. Includes React 19 API changes.
日本語の概要は準備中です。原文の説明を表示しています。
Review UI code for Web Interface Guidelines compliance. Use when asked to "review my UI", "check accessibility", "audit design", "review UX", or "check my site against best practices".
日本語の概要は準備中です。原文の説明を表示しています。
Builds production-quality, accessible, responsive user-facing UIs. Use when building or modifying interfaces and pages, creating components, implementing layouts, meeting WCAG accessibility requirements, managing state, or when the output needs to look and feel production-quality rather than AI-generated.
日本語の概要は準備中です。原文の説明を表示しています。
Apple's approach to interface design and fluid, physical motion, translated for the web. Use when building or reviewing gesture-driven UI, spring animations, drag/swipe/sheet interactions, momentum and interruptible transitions, translucent materials and depth, typography (optical sizing, tracking, leading), reduced-motion, or the design foundations (feedback, spatial consistency, restraint) behind Apple-style interfaces.
日本語の概要は準備中です。原文の説明を表示しています。
Before any PR that touches frontend, run the app and visually verify PT/EN pages on mobile and desktop. Use when finishing UI work or opening a frontend PR.
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for distinctive, intentional visual design when building new UI or reshaping an existing one. Helps with aesthetic direction, typography, and making choices that don't read as templated defaults.
日本語の概要は準備中です。原文の説明を表示しています。